10-KPeriod: FY2015

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2015

Filed February 12, 2016For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb (BMY) in its 2015 10-K filing demonstrates a strategic shift towards becoming a leading-edge specialty biopharmaceutical company, evidenced by significant divestitures and acquisitions. The company divested its diabetes and non-pharmaceutical businesses while acquiring companies like Cardioxyl Pharmaceuticals and Flexus Biosciences, focusing resources on core therapeutic areas such as oncology, immuno-oncology, immunoscience, cardiovascular disease, fibrosis, and genetically defined diseases. This strategic repositioning aims to address serious unmet medical needs and drive long-term value for investors. Financially, BMY reported total revenues of $16.56 billion for 2015, a modest increase from $15.88 billion in 2014, with the United States remaining its largest market (49% of revenues). The company's product portfolio shows a strong performance in key areas, with notable revenue streams from Eliquis (apixaban) and Opdivo (nivolumab) showing substantial growth, while established products like Abilify and Baraclude are facing or nearing patent exclusivity loss. Investors should monitor the impact of upcoming exclusivity expirations and the success of newer, high-growth products in the company's pipeline.

Financial Highlights

57 data points
Beta

Revenue

$16.56B

76.4% Gross Margin

Net Income

$1.56B

9.5% Net Margin

EPS (Diluted)

$0.93

Total Assets

$31.75B

Cash & Equivalents

$2.38B

Free Cash Flow

$1.28B

Financial Statements
Beta
Revenue$16.56B
Cost of Revenue$3.91B
Gross Profit$12.65B
R&D Expenses$5.92B
SG&A Expenses$4.84B
Operating Expenses$14.48B
Interest Expense$184.00M
Net Income$1.56B
EPS (Basic)$0.94
EPS (Diluted)$0.93
Shares Outstanding (Basic)1.67B
Shares Outstanding (Diluted)1.68B

Key Highlights

  • 1BMY is strategically transforming into a specialty biopharmaceutical company by divesting non-core assets (e.g., diabetes business) and acquiring new capabilities (e.g., Cardioxyl, Flexus).
  • 2The company is focusing its resources on high-growth therapeutic areas: oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis, and genetically defined diseases.
  • 3Total revenues for 2015 reached $16.56 billion, an increase from $15.88 billion in 2014, indicating revenue growth.
  • 4The United States continues to be the largest revenue-generating region, accounting for 49% of total revenues in 2015.
  • 5Key products like Opdivo (nivolumab) and Eliquis (apixaban) are showing significant revenue growth and are crucial for future expansion, with substantial exclusivity periods remaining.
  • 6Several key products, including Baraclude, Reyataz, Sustiva, and Abilify, are nearing or have already experienced the loss of basic market exclusivity in major markets like the U.S. and EU, which will likely impact future revenues.
  • 7The company is actively managing its product lifecycle, with strategic acquisitions and a focus on innovative medicines to offset potential declines from patent expirations.

Frequently Asked Questions

Bristol-Myers Squibb's primary strategic focus is to transform into a leading-edge specialty biopharmaceutical company. This involves concentrating on the discovery, development, and delivery of innovative medicines for serious unmet medical needs, with a core emphasis on oncology, immuno-oncology, immunoscience, cardiovascular disease, fibrosis, and genetically defined diseases. This strategy is supported by divesting non-core businesses like diabetes and acquiring new technologies and product candidates.

Several key products are nearing the end of their basic market exclusivity. For instance, Baraclude's U.S. exclusivity ended in 2014, and its EU exclusivity is ongoing until 2016. Reyataz and Sustiva franchises are expected to lose exclusivity in the U.S. in 2017. Abilify lost its U.S. exclusivity in 2015 and EU exclusivity in 2014. The loss of exclusivity can lead to significant and rapid declines in sales due to generic competition, which is a key risk factor for the company.

The primary growth drivers for BMY's future revenue are its newer, innovative products in therapeutic areas with significant unmet needs. Notably, Eliquis (apixaban) in cardiovascular and Opdivo (nivolumab) in oncology are showing strong revenue growth and have substantial market exclusivity periods extending to the mid-2020s. The company's continued focus on immuno-oncology and other core areas through R&D and strategic acquisitions is also expected to fuel future growth.

In 2015, the United States accounted for 49% of total revenues, slightly down from 51% in 2013, while Europe represented 21% (down from 24% in 2013). Japan showed a notable increase, rising from 5% in 2013 to 10% in 2015. This shift indicates a growing reliance on the U.S. market, a slight decrease in European contribution, and a significant expansion in Japan. Investors should monitor these regional trends, as market dynamics, regulatory environments, and competitive landscapes vary significantly across these geographies.